1 |
Mainardes RM, Urban MC, Cinto PO, Khalil NM, Chaud MV, Evangelista RC, Gremiao MP. Colloidal carriers for ophthalmic drug delivery. Curr Drug Targets 2005; 6: 363-371.
DOI
|
2 |
McMonnies C. Reactive oxygen species, oxidative stress, glaucoma and hyperbaric oxygen therapy. J Optom 2018; 11: 3-9.
DOI
|
3 |
Patel A, Cholkar K, Agrahari V, Mitra AK. Ocular drug delivery systems: An overview. World J Pharmacol 2013; 2: 47-64.
DOI
|
4 |
Phulke S, Kaushik S, Kaur S, Pandav SS. Steroid-induced glaucoma: An avoidable irreversible blindness. J Curr Glaucoma Pract 2017; 11: 67-72.
DOI
|
5 |
Pizzirani S. Definition, classification, and pathophysiology of canine glaucoma. Vet Clin North Am Small Anim Pract 2015; 45: 1127-1157.
DOI
|
6 |
Roy Chowdhury U, Hann CR, Stamer WD, Fautsch MP. Aqueous humor outflow: dynamics and disease. Invest Ophthalmol Vis Sci 2015; 56; 2993-3003.
DOI
|
7 |
Rupenthal ID, Daugherty AL. Ocular drugs and drug delivery systems - Current trends and future perspectives. Drug Discov Today 2019; 24: 1425-1426.
DOI
|
8 |
Russo R, Varano GP, Adornetto A, Nucci C, Corasaniti MT, Bagetta G, Morrone LA. Retinal ganglion cell death in glaucoma: Exploring the role of neuroinflammation. Eur J Pharmacol 2016; 15: 134-142.
|
9 |
Bae JH, Plummer CE, Kim J, Kim MS, Kim NS. Continuous ophthalmic treatment using an osmotic pump in a bull calf following surgical removal of an ocular dermoid: a case report. Vet Med Czech 2015; 60: 282-287.
|
10 |
Bergea B, Bodin L, Svedbergh B. Impact of intraocular pressure regulation on visual fields in open-angle glaucoma. Ophthalmology 1999; 106: 997-1004.
DOI
|
11 |
Bertaud S, Aragno V, Baudouin C, Labbe A. Primary openangle glaucoma. Rev Med Interne 2019; 40: 445-452.
DOI
|
12 |
Conlon R, Saheb H, Ahmed II. Glaucoma treatment trends: a review. Can J Ophthalmol 2017; 52: 114-124.
DOI
|
13 |
Hong S, Seong GJ, Hong YJ. Long-term intraocular pressure fluctuation and progressive visual field deterioration in patients with glaucoma and low intraocular pressures after a triple procedure. Arch of Ophthalmol 2007; 125: 1010-1013.
DOI
|
14 |
Huang AS, Minasyan L, Weinreb RN. Glaucoma-Intraocular Pressure Reduction. Handb Exp Pharmacol 2017; 242: 181-207.
|
15 |
Kim J, Kim MS. The evaluation of osmotic pump as glaucoma drug delivery system in normal dogs. Pak Vet J 2015; 35: 239-241.
|
16 |
Lee DA, Higginbotham EJ. Glaucoma and its treatment: a review. Am J Health Syst Pharm 2005; 62: 691-699.
DOI
|
17 |
Lee SS, Hughes P, Ross AD, Robinson MR. Biodegradable implants for sustained drug release in the eye. Pharm Res 2010; 27: 2043-2053.
DOI
|
18 |
Lusthaus J, Goldberg I. Current management of glaucoma. Med J Aust 2019; 210: 180-187.
DOI
|
19 |
Sheshala R, Kok YY, Ng JM, Thakur RR, Dua K. In situ gelling ophthalmic drug delivery system: An overview and its applications. Recent Pat Drug Deliv Formul 2015; 9: 237-248.
|
20 |
Lomelino C, McKenna R. Carbonic anhydrase inhibitors: a review on the progress of patent literature (2011-2016). Expert Opin Ther Pat 2016; 26: 947-956.
DOI
|
21 |
Agrahari V, Mandal A, Agrahari V, Trinh HM, Joseph M, Ray A, Hadji H, Mitra R, Pal D, Mitra AK, Agrahari V, Mandal A. A comprehensive insight on ocular pharmacokinetics. Drug Deliv Transl Res. 2016; 6: 735-754.
DOI
|